Decision-Making under Clinical Uncertainty: An in-depth Examination of Provider Perspectives on Adjuvant Chemotherapy for Stage II Colon Cancer

Adjuvant chemotherapy (ACT) improves average disease-free and overall survival among stage III colon and stage II and III rectal cancer patients.[1,2] However, benefits of ACT among stage II colon cancer patients continues to be debated, and nearly a quarter of stage II patients will have recurrence.[3] Controversy in this area stems from inconclusive clinical trial results,[4 –6] many of which have been insufficiently powered to detect treatment benefits among stage II patients[7,8], and challenges identifying which patients benefit most from ACT based on clinical risk features.[9]
Source: Patient Education and Counseling - Category: International Medicine & Public Health Authors: Source Type: research